The Effect of Tetranicotinoylfructose (Bradilan) on Fibrinolytic Activity, Platelet Stickiness and Some other Parameters

1975 ◽  
Vol 3 (6) ◽  
pp. 423-427 ◽  
Author(s):  
M E Benaim ◽  
H A Dewar
Keyword(s):  
Fatty Acids ◽  
Heart Disease ◽  
Side Effect ◽  
Fibrinolytic Activity ◽  
Type Ii ◽  
Peripheral Vascular ◽  
Type Iv ◽  
Cholesterol Levels ◽  
Term Trial

Twenty patients, of both sexes, suffering from ischaemic heart disease and/or atherosclerotic peripheral vascular disease have been studied in a long-term trial of tetranicotinoylfructose (Bradilan) by mouth. Cholesterol levels fell in Type II cases and triglycerides in Type IV, the falls being well maintained at 6 months. Significant falls in fibrinogen, free fatty acids, and platelet stickiness were also observed and maintained at 6 months. Fibrinolytic activity increased significantly and over a similar period of time. These results bore no relation to Fredrickson types. Only one important side-effect, namely flushing, was observed. It was infrequent and tolerable and it diminished with time and adjustment of dosage.

Plasma Fibrinolytic Activity Following Oral Anabolic Steroid Therapy

1975 ◽  
Vol 34 (01) ◽  
pp. 236-245 ◽  
Author(s):  
I. D Walker ◽  
J. F Davidson ◽  
P Young ◽  
J. A Conkie
Keyword(s):  
Heart Disease ◽  
Ischaemic Heart Disease ◽  
Anabolic Steroid ◽  
Fibrinolytic Activity ◽  
Anabolic Steroids ◽  
Long Term Effects ◽  
Lysis Time ◽  
Detailed Evaluation ◽  
Euglobulin Lysis Time

SummarySix anabolic steroids were assessed for their ability to enhance plasma fibrinolytic activity in males with ischaemic heart disease. Five 17α-alkylated steroids (Ethyloestrenol, Norethandrolone, Methandienone, Methylandrostenediol and Oxymetholone) were examined and all produced a significant increase in plasma plasminogen activator as measured by the euglobulin lysis time. The only non-17α-alkylated steroid studied (Methenolone acetate) failed to enhance fibrinolysis. The 17α-alkylated steroids studied all deserve more detailed evaluation of their long term effects on plasma fibrinolytic activity.

Macroangiopathy in type II diabetes

1983 ◽  
Vol 104 (4_Suppl) ◽  
pp. S75-S78
Author(s):  
Antti Aro
Keyword(s):  
Coronary Heart Disease ◽  
Heart Disease ◽  
Vascular Disease ◽  
Peripheral Vascular Disease ◽  
Type Ii Diabetes ◽  
Clinical Manifestations ◽  
Diabetic Patients ◽  
Type Ii ◽  
Peripheral Vascular ◽  
Middle Aged

ABSTRACT. Macroangiopathy is the most important cause of mortality and morbidity in type II diabetes. The atherosclerotic process in diabetes is similar to that found in non-diabetic subjects, but the laesions are more extensive and the clinical manifestations are more common in diabetic subjects than in the non-diabetic population. In diabetic patients from different populations, the prevalence of macroangiopathy is variable, and the relative frequency follows the pattern found in the respective non-diabetic populations. The relative risk of large vessel disease is in most populations higher for female than for male diabetics. Coronary heart disease is the most important manifestation of macroangiopathy while cerebrovascular disease and peripheral vascular disease are less frequent, although all these manifestations occur at increased frequency among middle-aged diabetic subjects. The incidence of peripheral vascular disease seems to increase with increasing duration of diabetes in middle-aged subjects, whereas coronary heart disease is particularly frequent in type II diabetes already at the time of the diagnosis. Key words: atherosclerosis, complications, diabetes mellitus, macroangiopathy, mortality.

scholarly journals LONG-TERM EFFECTS OF OMEGA-3 POLYUNSATURATED FATTY ACIDS ON THE COURSE OF ISCHEMIC HEART DISEASE IN PATIENTS AFTER ST-ELEVATION MYOCARDIAL INFARCTION AT THE BACKGROUND OF MULTIPLE-VESSEL LESION CORONARY ATHEROSCLEROSIS

2014 ◽  
Vol 13 (6) ◽  
pp. 32-37
Author(s):  
M. N. Sin’kova ◽  
T. V. Pepelyaeva ◽  
L. K. Isakov ◽  
N. I. Tarasov ◽  
A. T. Teplyakov
Keyword(s):  
Myocardial Infarction ◽  
Fatty Acids ◽  
Heart Disease ◽  
Polyunsaturated Fatty Acids ◽  
Ischemic Heart Disease ◽  
Ischemic Heart ◽  
Primary Pci ◽  
Omega 3 ◽  
St Elevation

Currently there is enough evidence for that the use of omega-3-faty acids compounds in ischemic heart disease is followed by the decrease of mortality, and the efficacy of this usage in multivessel coronary lesions after primary percutaneous intervention (PCI) has not been studied.Aim.To evaluate the efficacy of long-term intake of the omega-3-polyunsaturated fatty acids compounds on the course of ischemic heart disease at the background of multiple coronary lesion after primary PCI.Material and methods.Totally 101 patient included at the age of 35-70 y.o., who had underwent primary PCI for the myocardial infarction with ST elevation and multiple vessel lesion of coronary arteries. The patients were selected into 2 groups: 1 group (n=68) — conservative tactics with the standard pharmacotherapy; 2nd group (n=33) — Omacor was added to the standard therapy.Results.In 36 months of follow-up in the Omacor group there was significant decrease of repeated myocardial infarctions, decompensating heart failure, angina progression and rhythm disorders. In 2nd group patients during the 36-month follow-up a better antiischemic effect achieved with 80,9% decrease of angina from the baseline (p<0,047) and by 27,6% of the heart failure severity. The increase of exercise tolerance by the 6-minute walking test during 36 months was the highest in the 2nd group — by 65%.Conclusion.Long-term prescription of omega-3-polyunsaturated fatty acids in ST elevation myocardial infarction with multiple vessel coronary lesions after primary PCI leads to the improvement of clinical condition, which then leads to the increase of exercise tolerance and better life quality. 

Long-term experience with lovastatin treatment in patients with coronary heart disease and hyperlipoproteinaemia type II

1992 ◽  
Vol 13 (suppl B) ◽  
pp. 7-10 ◽  
Author(s):  
I. Zhukova ◽  
A. Yurenev ◽  
V. Kukharchuk ◽  
E. Pomerantsev ◽  
V. Titov ◽  
...  
Keyword(s):  
Coronary Heart Disease ◽  
Heart Disease ◽  
Type Ii ◽  
Long Term Experience ◽  
Hyperlipoproteinaemia Type ◽  
Lovastatin Treatment

Circulatory uses of prostaglandins

1984 ◽  
Vol 22 (26) ◽  
pp. 101-103
Keyword(s):  
Fatty Acids ◽  
Congenital Heart Disease ◽  
Arachidonic Acid ◽  
Heart Disease ◽  
Vascular Disease ◽  
Peripheral Vascular Disease ◽  
Congenital Heart ◽  
Peripheral Vascular ◽  
Naturally Occurring

Prostaglandins (PGs) are naturally-occurring fatty acids synthesised from arachidonic acid by cyclo-oxygenase enzymes. Two PGs with circulatory actions, alprostadil (PGE1; Prostin VR - Upjohn) and epoprostenol (prostacyclin, PGI2; Flolan - Wellcome, Cyclo-Prostin - Upjohn) are marketed in Britain. Both have already found a place; alprostadil for neonates with congenital heart disease, epoprostenol for use in extracorporeal circulations and in patients with severe peripheral vascular disease.

Gut Microbiota, Diet, and Heart Disease

2012 ◽  
Vol 95 (1) ◽  
pp. 24-30 ◽  
Author(s):  
Julia M W Wong ◽  
Amin Esfahani ◽  
Natasha Singh ◽  
Christopher R Villa ◽  
Arash Mirrahimi ◽  
...  
Keyword(s):  
Fatty Acids ◽  
Heart Disease ◽  
Gut Microbiota ◽  
Dietary Fiber ◽  
Short Chain Fatty Acids ◽  
Plant Foods ◽  
Bacterial Fermentation ◽  
Cholesterol Levels ◽  
Therapeutic Diets ◽  
Systemic Health

Abstract Modulation of the gut microbiota is an area of growing interest, particularly for its link to improving and maintaining the systemic health of the host. It has been suggested to have potential to reduce risk factors associated with chronic diseases, such as elevated cholesterol levels in coronary heart disease (CHD). Diets of our evolutionary ancestors were largely based on plant foods, high in dietary fiber and fermentable substrate, and our gut microbiota has evolved against a background of such diets. Therapeutic diets that mimic plant-based diets from the early phases of human evolution may result in drug-like cholesterol reductions. In contrast, typical Western diets low in dietary fiber and fermentable substrate, and high in saturated and trans fatty acids, are likely contributors to the increased need for pharmacological agents for cholesterol reduction. The gut microbiota of those consuming a Western diet are likely underutilized and depleted of metabolic fuels, resulting in a less than optimal gut microbial profile. As a result, this diet is mismatched to our archaic gut microbiota and, therefore, to our genome, which has changed relatively little since humans first appeared. While the exact mechanism by which the gut microbiota may modulate cholesterol levels still remains uncertain, end products of bacterial fermentation, particularly the short chain fatty acids (i.e., propionate), have been suggested as potential candidates. While more research is required to clarify the potential link between gut microbiota and CHD risk reduction, consuming a therapeutic diet rich in plant foods, dietary fiber, and fermentable substrate would be a useful strategy for improving systemic health, possibly by altering the gut microbiota.

Sign in / Sign up

Export Citation Format

Share Document